FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048722552> ?p ?o ?g. }

• W2048722552 endingPage "803" @default.
• W2048722552 startingPage "794" @default.
• W2048722552 abstract "Background Combinations of drug treatments based on bortezomib or lenalidomide plus steroids have resulted in very high response rates in multiple myeloma. However, most patients still relapse, indicating the need for novel combination partners to increase duration of response or to treat relapsed disease. We explored the antimyeloma activity of triple combinations of these well-established schemes with panobinostat, a novel deacetylase inhibitor with a multi-targeted profile.Design and Methods The activity of these combinations was explored in vitro in cell lines by using MTT and annex-in V, ex vivo by flow cytometry, and in vivo using two different murine models of human myeloma: one bearing a subcutaneous plasmacytoma and another with a disseminated myeloma. Moreover, gene expression profiling and immunohistochemical studies were performed.Results The addition of panobinostat (LBH589) to dexamethasone and either bortezomib or lenalidomide resulted in clear potentiation in multiple myeloma cell lines, freshly isolated plasma cells, and murine models of multiple myeloma. The quantification of the potency of these combinations by using the Chou-Talalay method showed synergistic combination indices for all of them. This effect derived from the deregulation of a cluster of genes that was completely different from the sum of genes affected by the single agents (895 and 1323 genes exclusively deregulated by panobinostat and dexamethasone plus bortezomib or lenalidomide, respectively). Functional experiments, such as annexin V staining, cell cycle analysis, and immunohistochemical studies also supported this potentiation. Anti-myeloma efficacy was confirmed in an extramedullary plasmacytoma model and a disseminated luciferized model, in which panobinostat also provided a marked benefit in bone disease.Conclusions The potent activity, together with the exclusive mechanistic profile, provides the rationale for the clinical evaluation of these drug combinations in multiple myeloma." @default.
• W2048722552 created "2016-06-24" @default.
• W2048722552 creator A5000020580 @default.
• W2048722552 creator A5004781521 @default.
• W2048722552 creator A5006172629 @default.
• W2048722552 creator A5014174665 @default.
• W2048722552 creator A5018071694 @default.
• W2048722552 creator A5029250422 @default.
• W2048722552 creator A5033029074 @default.
• W2048722552 creator A5051719313 @default.
• W2048722552 creator A5051903959 @default.
• W2048722552 creator A5052615349 @default.
• W2048722552 creator A5054921200 @default.
• W2048722552 creator A5071336872 @default.
• W2048722552 creator A5077742070 @default.
• W2048722552 creator A5089163384 @default.
• W2048722552 date "2009-11-30" @default.
• W2048722552 modified "2023-10-18" @default.
• W2048722552 title "In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma" @default.
• W2048722552 cites W1528961926 @default.
• W2048722552 cites W1574682683 @default.
• W2048722552 cites W1982972117 @default.
• W2048722552 cites W1984068295 @default.
• W2048722552 cites W1992538067 @default.
• W2048722552 cites W2016896026 @default.
• W2048722552 cites W2021954218 @default.
• W2048722552 cites W2026597875 @default.
• W2048722552 cites W2032907631 @default.
• W2048722552 cites W2034269086 @default.
• W2048722552 cites W2047959990 @default.
• W2048722552 cites W2052169053 @default.
• W2048722552 cites W2053441492 @default.
• W2048722552 cites W2057196686 @default.
• W2048722552 cites W2066000727 @default.
• W2048722552 cites W2066295909 @default.
• W2048722552 cites W2066800926 @default.
• W2048722552 cites W2071989867 @default.
• W2048722552 cites W2074174622 @default.
• W2048722552 cites W2077945404 @default.
• W2048722552 cites W2079029980 @default.
• W2048722552 cites W2087507084 @default.
• W2048722552 cites W2096207943 @default.
• W2048722552 cites W2096738564 @default.
• W2048722552 cites W2099380130 @default.
• W2048722552 cites W2100972878 @default.
• W2048722552 cites W2122231588 @default.
• W2048722552 cites W2123068491 @default.
• W2048722552 cites W2124560610 @default.
• W2048722552 cites W2127971712 @default.
• W2048722552 cites W2142112710 @default.
• W2048722552 cites W2155061120 @default.
• W2048722552 cites W2567356540 @default.
• W2048722552 cites W2587332589 @default.
• W2048722552 cites W2589286928 @default.
• W2048722552 cites W2593281873 @default.
• W2048722552 doi "https://doi.org/10.3324/haematol.2009.015495" @default.
• W2048722552 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2864386" @default.
• W2048722552 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19951978" @default.
• W2048722552 hasPublicationYear "2009" @default.
• W2048722552 type Work @default.
• W2048722552 sameAs 2048722552 @default.
• W2048722552 citedByCount "143" @default.
• W2048722552 countsByYear W20487225522012 @default.
• W2048722552 countsByYear W20487225522013 @default.
• W2048722552 countsByYear W20487225522014 @default.
• W2048722552 countsByYear W20487225522015 @default.
• W2048722552 countsByYear W20487225522016 @default.
• W2048722552 countsByYear W20487225522017 @default.
• W2048722552 countsByYear W20487225522018 @default.
• W2048722552 countsByYear W20487225522019 @default.
• W2048722552 countsByYear W20487225522020 @default.
• W2048722552 countsByYear W20487225522021 @default.
• W2048722552 countsByYear W20487225522022 @default.
• W2048722552 countsByYear W20487225522023 @default.
• W2048722552 crossrefType "journal-article" @default.
• W2048722552 hasAuthorship W2048722552A5000020580 @default.
• W2048722552 hasAuthorship W2048722552A5004781521 @default.
• W2048722552 hasAuthorship W2048722552A5006172629 @default.
• W2048722552 hasAuthorship W2048722552A5014174665 @default.
• W2048722552 hasAuthorship W2048722552A5018071694 @default.
• W2048722552 hasAuthorship W2048722552A5029250422 @default.
• W2048722552 hasAuthorship W2048722552A5033029074 @default.
• W2048722552 hasAuthorship W2048722552A5051719313 @default.
• W2048722552 hasAuthorship W2048722552A5051903959 @default.
• W2048722552 hasAuthorship W2048722552A5052615349 @default.
• W2048722552 hasAuthorship W2048722552A5054921200 @default.
• W2048722552 hasAuthorship W2048722552A5071336872 @default.
• W2048722552 hasAuthorship W2048722552A5077742070 @default.
• W2048722552 hasAuthorship W2048722552A5089163384 @default.
• W2048722552 hasBestOaLocation W20487225521 @default.
• W2048722552 hasConcept C104317684 @default.
• W2048722552 hasConcept C126322002 @default.
• W2048722552 hasConcept C134459356 @default.
• W2048722552 hasConcept C143998085 @default.
• W2048722552 hasConcept C150903083 @default.
• W2048722552 hasConcept C203014093 @default.
• W2048722552 hasConcept C207001950 @default.
• W2048722552 hasConcept C25602115 @default.

• next